Tasly Pharmaceuticals

Explore the latest insights on Tasly Pharmaceuticals and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Tasly Pharmaceuticals’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.Fineline Info & Tech (Flcube.com) provides you with comprehensive information about Tasly Pharmaceuticals, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about Tasly Pharmaceuticals please access Flcube.com

HUTCHMED Initiates Phase Ia Global Trial of HMPL-A830 – First‑in‑Class KRAS‑Payload Antibody‑Targeted Conjugate Licensed to GSK for up to USD 1.295 Billio
CompanyDrug

HUTCHMED Initiates Phase Ia Global Trial of HMPL-A830 – First‑in‑Class KRAS‑Payload Antibody‑Targeted Conjugate Licensed to GSK for up to USD 1.295 Billion

HUTCHMED (China) Limited (NASDAQ: HCM, HKG: 0013) announced that it has initiated the Phase Ia portion of a global clinical trial evaluating HMPL-A830, a potential first‑in‑class antibody‑targeted conjugate (ATTC), for…

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Tasly Pharma Partners with Beijing Neurosurgical Institute on Dual-Target CAR-T Therapy – RMB 240M Investment Advances CD44/CD133 Autologous Treatment for Recurrent Glioblastoma

Tasly Pharma Gains NMPA Green Light for CAR-T Therapy Clinical Study in Recurrent Glioblastoma
CompanyDrug

Tasly Pharma Gains NMPA Green Light for CAR-T Therapy Clinical Study in Recurrent Glioblastoma

Tasly Pharma's NR-20201 Receives NMPA Approval for Acute Ischemic Stroke Trial
CompanyDrug

Tasly Pharma’s NR-20201 Receives NMPA Approval for Acute Ischemic Stroke Trial

CR Sanjiu Gains SASAC Approval for Tasly Pharma Acquisition
CompanyDeals

CR Sanjiu Gains SASAC Approval for Tasly Pharma Acquisition

Tasly Pharma Receives NMPA Approval for Generic Lioresal (Baclofen) Oral Solution
CompanyDrug

Tasly Pharma Receives NMPA Approval for Generic Lioresal (Baclofen) Oral Solution

Tasly Pharmaceuticals Gets FDA Approval for Acute Ischemic Stroke Cell Therapy Clinical Study
CompanyDrug

Tasly Pharmaceuticals Gets FDA Approval for Acute Ischemic Stroke Cell Therapy Clinical Study

CompanyDeals

CR Sanjiu to Acquire Significant Stake in Tasly Pharmaceuticals in a Deal Valued at $870 Million

CompanyDrug

Tasly Pharmaceuticals Gets NMPA Go-Ahead for Clinical Trial of Stem Cell Therapy in Heart Failure

Show More